B lymphocytes as effector cells in the immunotherapy of cancer

Journal of Surgical Oncology

Volumn 105, Issue 4, 2012, Pages 431-435

  Namm, Jukes P ^a,b   Li, Qiao ^a   Lao, Xiangming ^a,c   Lubman, David M ^a   He, Jintang ^a   Liu, Yashu ^a   Zhu, Jianhui ^a   Wei, Shuang ^a   Chang, Alfred E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b LOMA LINDA UNIVERSITY   (United States)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

adoptive immunotherapy; antibody; B cells; tumor antigen

Indexed keywords

ANTIBODY; ANTIGEN SPECIFIC ANTIBODY; BEVACIZUMAB; CETUXIMAB; IPILIMUMAB; RITUXIMAB; UNCLASSIFIED DRUG; VERVOY;

ADOPTIVE IMMUNOTHERAPY; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL INTERACTION; COLORECTAL CANCER; EFFECTOR CELL; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTE SUBSETS; HUMANS; NEOPLASMS; T-LYMPHOCYTES;

EID: 84857059418     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22093     Document Type: Review

References (42)

1. LeBien TW, Tedder TF,: B lymphocytes: How they develop and function. Blood 2008; 112: 1570-1580.
2. Fagraeus A,: The plasma cellular reaction and its relation to the formation of antibodies in vitro. J Immunol 1948; 58: 1-13.
3. Cooper MD, Peterson RD, Good RA,: Delineation of the thymic and bursal lymphoid systems in the chicken. Nature 1965; 205: 143-146.
4. Cooper MD, Raymond DA, Peterson RD, et al.: The functions of the thymus system and the bursa system in the chicken. J Exp Med 1966; 123: 75-102.
5. Ron Y, De Baetselier P, Gordon J, et al.: Defective induction of antigen-reactive proliferating T cells in B cell-deprived mice. Eur J Immunol 1981; 11: 964-968. (Pubitemid 12212147)
6. Ron Y, Sprent J,: T cell priming in vivo: A major role for B cells in presenting antigen to T cells in lymph nodes. J Immunol 1987; 138: 2848-2856. (Pubitemid 17072758)
7. Janeway CA, Jr. , Ron J, Katz ME,: The B cell is the initiating antigen-presenting cell in peripheral lymph nodes. J Immunol 1987; 138: 1051-1055. (Pubitemid 17017883)
8. Lanzavecchia A,: Antigen-specific interaction between T and B cells. Nature 1985; 314: 537-539. (Pubitemid 15124262)
9. Harris DP, Haynes L, Sayles PC, et al.: Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000; 1: 475-482.
10. Harris DP, Goodrich S, Mohrs K, et al.: Cutting edge: the development of IL-4-producing B cells (B effector 2cells) is controlled by IL-4, IL-4 receptor alpha, and Th2 cells. J Immunol 2005; 175: 7103-7107. (Pubitemid 41713402)
11. Harris DP, Goodrich S, Gerth AJ, et al.: Regulation of IFN-gamma production by B effector 1 cells: Essential roles for T-bet and the IFN-gamma receptor. J Immunol 2005; 174: 6781-6790. (Pubitemid 40705641)
12. Mizoguchi A, Bhan AK,: A case for regulatory B cells. J Immunol 2006; 176: 705-710. (Pubitemid 43099663)
13. Mauri C, Ehrenstein MR,: The 'short' history of regulatory B cells. Trends Immunol 2008; 29: 34-40.
14. Vetrie D, Vorechovsky I, Sideras P, et al.: The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993; 361: 226-233. (Pubitemid 23034471)
15. Tsukada S, Saffran DC, Rawlings DJ, et al.: Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993; 72: 279-290. (Pubitemid 23044942)
16. Bacchelli C, Buckridge S, Thrasher AJ, et al.: Translational mini-review series on immunodeficiency: Molecular defects in common variable immunodeficiency. Clin Exp Immunol 2007; 149: 401-409. (Pubitemid 47256166)
17. Brodt P, Gordon J,: Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. J Immunol 1978; 121: 359-362. (Pubitemid 8384890)
18. Monach PA, Schreiber H, Rowley DA,: CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation 1993; 55: 1356-1361. (Pubitemid 23183251)
19. Chapoval AI, Fuller JA, Kremlev SG, et al.: Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J Immunol 1998; 161: 6977-6984. (Pubitemid 28562246)
20. Qin Z, Richter G, Schuler T, et al.: B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998; 4: 627-630. (Pubitemid 28237366)
21. Perricone MA, Smith KA, Claussen KA, et al.: Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother (1997) 2004; 27: 273-281. (Pubitemid 38833323)
22. Shah S, Divekar AA, Hilchey SP, et al.: Increased rejection of primary tumors in mice lacking B cells: Inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer 2005; 117: 574-586. (Pubitemid 41504545)
23. Inoue S, Leitner WW, Golding B, et al.: Inhibitory effects of B cells on antitumor immunity. Cancer Res 2006; 66: 7741-7747. (Pubitemid 44289234)
24. Watt V, Ronchese F, Ritchie D,: Resting B cells suppress tumor immunity via an MHC class-II dependent mechanism. J Immunother (1997) 2007; 30: 323-332. (Pubitemid 46586648)
25. Joao C, Ogle BM, Gay-Rabinstein C, et al.: B cell-dependent TCR diversification. J Immunol 2004; 172: 4709-4716. (Pubitemid 38456391)
26. Crowley MT, Reilly CR, Lo D,: Influence of lymphocytes on the presence and organization of dendritic cell subsets in the spleen. J Immunol 1999; 163: 4894-4900. (Pubitemid 29501254)
27. Moulin V, Andris F, Thielemans K, et al.: B lymphocytes regulate dendritic cell (DC) function in vivo: Increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med 2000; 192: 475-482. (Pubitemid 30666248)
28. DiLillo DJ, Yanaba K, Tedder TF,: B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: Therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 2010; 184: 4006-4016.
29. Schultze JL, Michalak S, Seamon MJ, et al.: CD40-activated human B cells: An alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997; 100: 2757-2765. (Pubitemid 28007544)
30. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, et al.: Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: Potential for clinical application. Blood 2002; 99: 3319-3325. (Pubitemid 34525313)
31. Kondo E, Topp MS, Kiem HP, et al.: Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol 2002; 169: 2164-2171. (Pubitemid 34857684)
32. Lapointe R, Bellemare-Pelletier A, Housseau F, et al.: CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003; 63: 2836-2843. (Pubitemid 36667155)
33. Coughlin CM, Vance BA, Grupp SA, et al.: RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: Implications for pediatric immunotherapy. Blood 2004; 103: 2046-2054. (Pubitemid 38326219)
34. Van den Bosch GA, Ponsaerts P, Nijs G, et al.: Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells. Clin Exp Immunol 2005; 139: 458-467. (Pubitemid 40333257)
35. Chung Y, Kim BS, Kim YJ, et al.: CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo. Cancer Res 2006; 66: 6843-6850. (Pubitemid 44085645)
36. Tamada K, Harada M, Okamoto T, et al.: Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2. Cancer Immunol Immunother 1995; 41: 339-347. (Pubitemid 26045104)
37. Harada M, Okamoto T, Kurosawa S, et al.: The antitumor activity induced by the in vivo administration of activated B cells bound to anti-CD3 monoclonal antibody. Cell Immunol 1995; 161: 132-137.
38. Kawakami K, Terabe M, Kawakami M, et al.: Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain. Cancer Res 2006; 66: 4434-4442.
39. Li Q, Teitz-Tennenbaum S, Donald EJ, et al.: In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J Immunol 2009; 183: 3195-3203.
40. Li Q, Lao X, Pan Q, et al.: Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res 2011 17: 4987-4995.
41. Kemp TJ, Moore JM, Griffith TS,: Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation. J Immunol 2004; 173: 892-899. (Pubitemid 38924262)
42. Lopez DM, Blomberg BB, Padmanabhan RR, et al.: Nuclear disintegration of target cells by killer B lymphocytes from tumor-bearing mice. FASEB J 1989; 3: 37-43. (Pubitemid 19042563)